LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ligand Pharmaceuticals Inc (LGND) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive catalysts such as bullish analyst ratings and a strong revenue growth trend, the significant insider selling, declining net income, and lack of recent trading signals suggest a cautious approach. Holding the stock or waiting for a better entry point is recommended.
The technical indicators show a mixed picture. The MACD is positive and contracting, indicating a potential bullish trend. RSI is neutral at 56.003, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level of 211.256, with resistance at 223.384 and support at 199.127. This suggests limited immediate upside potential.
Analysts have given positive ratings with increased price targets (e.g., Oppenheimer raised the target to $277, citing strong royalty revenue and promising portfolio assets).
Revenue growth of 39.37% YoY in Q4 2025, indicating strong top-line performance.
Gross margin increased to 81.42%, up 9.91% YoY, reflecting operational efficiency.
Insiders are selling heavily, with a 5349.67% increase in selling activity over the last month.
Net income dropped significantly by -244.06% YoY in Q4 2025, and EPS declined by -232.32% YoY, indicating profitability challenges.
No recent news or event-driven catalysts to support a strong buy case.
In Q4 2025, revenue increased to $59.67M, up 39.37% YoY, showing strong top-line growth. However, net income dropped to $44.78M, down -244.06% YoY, and EPS fell to 2.17, down -232.32% YoY. Gross margin improved to 81.42%, up 9.91% YoY, but the decline in profitability is a concern.
Analysts are bullish on LGND. BofA initiated coverage with a Buy rating and a $244 price target, citing a strong portfolio and lean cost structure. Oppenheimer raised the price target to $277, highlighting promising portfolio assets and royalty revenue. H.C. Wainwright increased the price target to $239 after positive Phase 3 trial results for QTORIN. Analysts believe the stock is underappreciated but acknowledge profitability challenges.
